Myriad Genetics, Inc.

Other

Myrexis, Inc.

Myriad Pharmaceuticals, Inc.

Manfredi, John

Kenton Zavitz

Scott Morham

Mark B Anderson

Warren S Weiner

Rachel M Slade

Ruth J Walton

Yevgeniya Klimova

Robert J Halter

Jon Adam Willardsen

Ashantai J Yungai

Daniel Wettstein

Adrian Hobden

John P Manfredi

Christine A Klein

Andrew Gassman

Leena Bhoite

Rachel Slade

The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).

Compounds for Alzheimer's disease

The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(&#x2550;O)OH, -L-CH&#x2550;CHC(&#x2550;O)OH, -L-C(&#x2550;O)NH, -L-C(&#x2550;O)NH(Calkyl), -L-C(&#x2550;O)N(Calkyl), -L-S(&#x2550;O)(Calkyl), -L-S(&#x2550;O)NH, -L-S(&#x2550;O)N(Calkyl), -L-S(&#x2550;O)NH(Calkyl), -L-C(&#x2550;O)NHOH, -L-C(&#x2550;O)CHNH, -L-C(&#x2550;O)CHOH, -L-C(&#x2550;O)CHSH, -L-C(&#x2550;O)NHCN, -L-NHC(&#x2550;O)OR, -L-C(&#x2550;O)NHR, -L-NH(C&#x2550;O)NHR, -L-C(&#x2550;O)N(R), -L-NH(C&#x2550;O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.

The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the formation of cells displaying HIV late-domain phenotype in the body of the patient.

Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface

Compounds for alzheimer's disease

Isolated protein complexes are provided comprising Tsg101 and HIV GAG or GAGp6. The protein complexes are useful in screening assays for selecting compounds effective in modulating the Tsg101-HIV GAG or GAGp6 interaction within the protein complexes.

TSG101-GAG interaction and use thereof

Isolated protein complexes are provided comprising Tsg101 and HIV GAGp6. The protein complexes are useful in screening assays for selecting compounds effective in modulating the Tsg101-HIV GAGp6 interaction within the protein complexes.

Tsg101-GAGp6 interaction and use thereof

Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a therapeutic peptide or a derivative thereof.

Therapeutic compositions and methods for treating viral infection

Growing community of inventors

Salt Lake City, UT, United States of America

Kenton Zavitz